Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1-28. (cancelled)

29. (currently amended) A method of treating cancer in a patient, said method comprising administering to said patient [[the]] a pharmaceutical composition ~~of claim 28~~ comprising an isolated antibody capable of binding to human tissue factor, wherein said antibody does not inhibit tissue factor mediated blood coagulation compared to a normal plasma control and causes an increase in percent cytotoxicity of tissue factor positive cells compared to a negative control antibody, wherein said antibody is administered to the patient at a dosage of 0.001 mg/kg to 100 mg/kg of the patient's body weight, and wherein said cancer is selected from the group consisting of non-small cell lung cancer, breast cancer, colon cancer, and prostate cancer.

30. (original) The method of claim 29, wherein said cancer is a solid tumor.

31. (cancelled)

32. (original) The method of claim 29, wherein said pharmaceutical composition comprises an antibody conjugated to a cytotoxic agent.

33. (currently amended) A method of detecting cancer, said method comprising:

providing ~~the antibody of claim 8~~ to a sample or subject ~~and~~ a pharmaceutical composition comprising an isolated antibody conjugated to a detectable agent capable of binding to human tissue factor, wherein said antibody does not inhibit tissue factor mediated blood coagulation compared to a normal plasma control and causes an increase in percent cytotoxicity of tissue factor positive cells compared to a negative control antibody, wherein said antibody is administered to the subject at a dosage of 0.001 mg/kg to 100 mg/kg of the subject's body weight; and

detecting the binding of said detectable agent to a cancer cell, wherein said cancer is selected from the group consisting of non-small cell lung cancer, breast cancer, colon cancer, and prostate cancer.

34-77. (cancelled)

78. (currently amended) A method of treating cancer in a patient, said method comprising administering to said patient [[the]] a pharmaceutical composition ~~of claim 77~~ comprising an isolated antibody capable of binding to human tissue factor, wherein said antibody does not inhibit tissue factor mediated blood coagulation compared to a normal plasma control, is conjugated to a cytotoxic agent or a detectable agent and causes an increase in percent cytotoxicity of tissue factor positive cells compared to a negative control antibody, wherein said antibody is administered to the patient at a dosage of 0.001 mg/kg to 100 mg/kg of the patient's body weight, and wherein said

cancer is selected from the group consisting of non-small cell lung cancer, breast cancer, colon cancer, and prostate cancer.

79. (previously presented) The method of claim 78, wherein said cancer is a solid tumor.

80-81. (cancelled)

82. (new) The method of claim 29, wherein said antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, single chain antibody, humanized antibody, and antibody product of a Fab expression library.

83. (new) The method of claim 29, wherein said antibody is a modified antibody.

84. (new) The method of claim 29, wherein said antibody is a monoclonal antibody.

85. (new) The method of claim 29, wherein said antibody is a chimeric antibody.

86. (new) The method of claim 29, wherein said antibody is a single chain antibody.

87. (new) The method of claim 29, wherein said antibody is a humanized antibody.

88. (new) The method of claim 29, wherein said antibody is an antibody product of a Fab expression library.

89. (new) The method of claim 29, wherein said antibody is conjugated to a detectable agent.

90. (new) The method of claim 89, wherein said detectable agent is selected from the group consisting of: an enzyme, prosthetic group, fluorescent material, luminescent material, bioluminescent material, radioactive material, positron emitting metal using a positron emission tomography, and nonradioactive paramagnetic metal ion.

91. (new) The method of claim 84, wherein said monoclonal antibody binds to the same epitope as a monoclonal antibody produced by a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

92. (new) The method of claim 84, wherein said monoclonal antibody competes for binding to the same epitope as a monoclonal antibody produced by a

hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

93. (new) The method of claim 29, wherein said antibody is obtained from a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

94. (new) The method of claim 29, wherein said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 8, 19, 21 and 27.

95. (new) The method of claim 29, wherein said antibody comprises an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 7, 18, 20 and 26.

96. (new) The method of claim 32, wherein said cytotoxic agent is selected from the group consisting of: a paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin,

actinomycin D, 1-dehydrotestosterone, glucocorticoid, procaine, tetracaine, lidocaine, propranolol, puromycin, and a radioisotope.

97. (new) The method of claim 33, wherein said antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, single chain antibody, humanized antibody, and antibody product of a Fab expression library.

98. (new) The method of claim 33, wherein said antibody is a modified antibody.

99. (new) The method of claim 33, wherein said antibody is a monoclonal antibody.

100. (new) The method of claim 33, wherein said antibody is a chimeric antibody.

101. (new) The method of claim 33, wherein said antibody is a single chain antibody.

102. (new) The method of claim 33, wherein said antibody is a humanized antibody.

103. (new) The method of claim 33, wherein said antibody is an antibody product of a Fab expression library.

104. (new) The method of claim 33, wherein said detectable agent is selected from the group consisting of: an enzyme, prosthetic group, fluorescent material, luminescent material, bioluminescent material, radioactive material, positron emitting metal using a positron emission tomography, and nonradioactive paramagnetic metal ion.

105. (new) The method of claim 99, wherein said monoclonal antibody binds to the same epitope as a monoclonal antibody produced by a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

106. (new) The method of claim 99, wherein said monoclonal antibody competes for binding to the same epitope as a monoclonal antibody produced by a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

107. (new) The method of claim 33, wherein said antibody is obtained from a a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

108. (new) The method of claim 33, wherein said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 8, 19, 21 and 27.

109. (new) The method of claim 33, wherein said antibody comprises an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 7, 18, 20 and 26.

110. (new) The method of claim 78, wherein said antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, single chain antibody, humanized antibody, and antibody product of a Fab expression library.

111. (new) The method of claim 78, wherein said antibody is a modified antibody.

112. (new) The method of claim 78, wherein said antibody is a monoclonal antibody.

113. (new) The method of claim 78, wherein said antibody is a chimeric antibody.

114. (new) The method of claim 78, wherein said antibody is a single chain antibody.

115. (new) The method of claim 78, wherein said antibody is a humanized antibody.

116. (new) The method of claim 78, wherein said antibody is an antibody product of a Fab expression library.

117. (new) The method of claim 78, wherein said detectable agent is selected from the group consisting of: an enzyme, prosthetic group, fluorescent material, luminescent material, bioluminescent material, radioactive material, positron emitting metal using a positron emission tomography, and nonradioactive paramagnetic metal ion.

118. (new) The method of claim 112, wherein said monoclonal antibody binds to the same epitope as a monoclonal antibody produced by a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

119. (new) The method of claim 112, wherein said monoclonal antibody competes for binding to the same epitope as a monoclonal antibody produced by a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a monoclonal antibody produced by a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a monoclonal antibody produced by a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

120. (new) The method of claim 78, wherein said antibody is obtained from a hybridoma cell line TF260 deposited under ATCC Accession No. PTA-5197, a hybridoma cell line TF278 deposited under ATCC Accession No. PTA-5676, or a hybridoma cell line TF392 deposited under ATCC Accession No. PTA-5677.

121. (new) The method of claim 78, wherein said antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 8, 19, 21 and 27.

122. (new) The method of claim 78, wherein said antibody comprises an amino acid sequence encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 5, 7, 18, 20 and 26.

123. (new) The method of claim 78, wherein said cytotoxic agent is selected from the group consisting of: a paclitaxol, cytochalasin B, gramicidin D, ethidium

bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoid, procaine, tetracaine, lidocaine, propranolol, puromycin, and a radioisotope.

124. (new) The method of claim 29, wherein said pharmaceutical composition comprises a therapeutically effective amount of said antibody and a pharmaceutically acceptable carrier.

125. (new) The method of claim 78, wherein said pharmaceutical composition comprises a therapeutically effective amount of said antibody and a pharmaceutically acceptable carrier.